Cancer immunotherapy comes of age
Explore this paper's citation graph
Summary
In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
- Type
- review
- Published
- 2011-12-21
- Cited by
- 3,923
- References
- 107
- Access
- Open access
- OpenAlex
- https://openalex.org/W2044835625
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4403912
Keywords
Ipilimumab, Medicine, Immunosuppression, Immunotherapy, Context (archaeology)
References
- Dendritic cells: specialized and regulated antigen processing machines.
- A Commotion in the Blood: Life, Death, and the Immune System
- Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
- Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy1
- High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
- Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses
- PD‐1/PD‐L1 pathway and T‐cell exhaustion in chronic hepatitis virus infection
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
- Ido expression by dendritic cells: tolerance and tryptophan catabolism
- Adoptive cell transfer: a clinical path to effective cancer immunotherapy
- Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation.
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
- Role of LAG-3 in regulatory T cells.
- Cancer immunotherapy: moving beyond current vaccines
- CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers
- Myeloid-derived-suppressor cells as regulators of the immune system
- Herceptin: mechanisms of action and resistance.
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- A listing of human tumor antigens recognized by T cells
Cited by
- Competition driven cancer immunoediting
- Chemotherapy, immunity and microbiota—a new triumvirate?
- Major Histocompatibility Complex Class II+ Invariant Chain Negative Breast Cancer Cells Present Unique Peptides that Activate Tumor-specific T Cells from Breast Cancer Patients*
- RNA aptamers targeting cancer stem cell marker CD133.
- Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy
- Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
- Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP.
- Covalently Coupled Immunostimulant Heterodimers
- Intratumoral Immunization: A New Paradigm for Cancer Therapy
- Targeted immunotherapy for non-small cell lung cancer.
- Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
- Pentoxifylline Inhibits WNT Signalling in β-Cateninhigh Patient-Derived Melanoma Cell Populations
- Metronomic chemotherapy and immunotherapy in cancer treatment.
- Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
- Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis
- Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
- Cancer immunology and melanoma immunotherapy
- Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
Related papers
- Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients
- The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
- Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
- Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
- Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma
- Cost-effectiveness of nivolumab in advanced melanoma: a drug review
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
- Nivolumab + ipilimumab ups melanoma response.
- Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer
- Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies